# Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

> **NCT02635984** · PHASE3 · COMPLETED · sponsor: **Augusta University** · enrollment: 108 (actual)

## Conditions studied

- Complications of Bone Marrow Transplant
- Hematologic Neoplasms

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02635984
- **Lead sponsor:** Augusta University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2018-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02635984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02635984, "Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02635984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*